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Abstract
Introduction: Triple-negative breast cancer (TNBC), which is characterized by negativity for estrogen receptor,
progesterone receptor and human epidermal growth factor receptor 2 (HER2), is a high risk breast cancer that lacks
specific targets for treatment selection. Chemotherapy is, therefore, the primary systemic modality used in the
treatment of this disease, but reliable parameters to predict the chemosensitivity of TNBC have not been clinically
available.
Methods: A total of 190 TNBC patients who had undergone a curative resection of a primary breast cancer were
enrolled. The adjuvant chemotherapy was performed for 138 (73%) of 190 TNBC cases; 60 cases had an
anthracyclin-based regimen and 78 a 5-fluorouracil-based regimen. The prognostic value of E-cadherin, Ki67 and
p53 expression in the outcome of TNBC patients with adjuvant chemotherapy was evaluated by
immunohistochemistry.
Results: The adjuvant therapy group, especially those with Stage II TNBC, had a more favorable prognosis than the
surgery only group (P = 0.0043), while there was no significant difference in prognosis between the anthracyclin-
based regimen and 5-fluorouracil-based regimen. Patients with E-cadherin-negative and Ki67-positive expression
showed significantly worse overall survival time than those with either E-cadherin-positive or Ki67-negative
expression (P < 0.001). Multivariate analysis showed that the combination of E-cadherin-negative and Ki67-positive
expression was strongly predictive of poor overall survival (P = 0.004) in TNBC patients receiving adjuvant
chemotherapy. In contrast, p53 status was not a specific prognostic factor.
Conclusions: Adjuvant therapy is beneficial for Stage II TNBC patients. The combination of E-cadherin and Ki67 status
might be a useful prognostic marker indicating the need for adjuvant chemotherapy in Stage II TNBC patients.
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Introduction
Breast cancer is a heterogeneous disease and is currently
divided into subtypes in accordance with the status of
estrogen receptor (ER), progesterone receptor (PR) and
human epidermal growth factor receptor 2 (HER2)
[1-3]. These subtypes display significant diversity in
regard to the clinical behavior, outcome and response to
therapy [4-6]. One of these subtypes, triple-negative
breast cancer (TNBC), which is characterized by a lack
of ER, PR and HER2 expression, accounts for 10% to
20% of all breast cancers, and has a high probability of
early tumor relapse after diagnosis, increased propensity
to develop brain metastases, and rapid risk of death
after tumor relapse [1,7-9]; adjuvant therapy is thus
necessary for patients with TNBC [10]. However, since
TNBC lacks specific targets for treatment selection,
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the treatment of this disease [11].
A recent study has demonstrated that TNBC is more
chemosensitive than other subtypes of breast cancer
[12]. Kennedy et al. reported that patients with TNBC
who underwent adjuvant chemotherapy were 52% less
likely to die compared with those who received neoadju-
vant chemotherapy or no/unknown chemotherapy [13],
suggesting that the benefit of primary tumor removal
followed by early initiation of adjuvant therapy may be
most relevant for the TNBC subgroup. Anthracyclines
(epirubicin and doxorubicin), alkylating agents (cyclo-
phosphamide), and 5-fluorouracil (5FU) are the standard
of care in the treatment of breast cancer in the adjuvant
setting.
The selection of patients with chemosensitive tumors
before initiating chemotherapy would be important for
avoiding potential therapy-related complications. Predic-
tive factors of response would help to assess the
expected individual benefit of this treatment. Different
breast cancer subgroups may have different predictive
markers of response to chemotherapy. Thus, it is of the
highest importance to elucidate prognostic factors and
key biomarkers of triple-negative cancers. Although var-
ious in vivo and in vitro approaches have been used in
an attempt to predict the chemosensitivity of TNBC
[14-16], reliable parameters have not been clinically
available. The purpose of this study was to evaluate can-
didate predictive markers for chemosensitivity in TNBC.
E-cadherin, one of the cell adhesion molecules, is
reported to be related to the invasion of cancer cells,
and a low-level expression ofE - c a d h e r i ni sc o n s i d e r e d
to be an indication of poor prognosis [17-22]. Although
E-cadherin is one of the markers for chemosensitivity in
several types of carcinomas [23-25], the significance of
E-cadherin for chemosensitivity of TNBC remains
unclear [25]. Ki67 has been reported to be a candidate
predictive marker for chemosensitivity in all types of
breast cancer [16,26], but the predictive value of Ki67
for chemoresponse of TNBC has not been clarified. p53
status is one of the most investigated predictive biomar-
kers for the efficacy of anthracycline-containing che-
motherapy. Despite the many studies, however, the
results have been inconsistent, with some studies report-
ing an association between p53 expression and tumor
response to neoadjuvant anthracyclines [27-29], whereas
other reports have associated p53 overexpression with
both resistance [30,31] and sensitivity [32,33] to preo-
perative anthracycline-containing chemotherapy. TNBC
is more likely to carry TP53 gene mutations. In the pre-
sent study, we evaluated the prognostic value of E-cad-
herin, Ki67 and p53 expression for the outcome of
adjuvant chemotherapy in 190 cases of TNBC, which
were culled from 1,036 cases of all types of breast
carcinomas.
Methods
Patients
This study investigated a consecutive series of 1,063
cases of sporadic invasive breast carcinoma. Because E-
cadherin is functionally silenced in invasive lobular car-
cinoma [34], 27 cases of invasive lobular carcinomas
were excluded. Then a total of 1,036 breast cancer cases
were enrolled in this study. All patients had received a
curative operation of a mastectomy or a conservative
surgery with axillary lymph node dissection in Osaka
City University Hospital or Osaka City General Hospital
from 2000 to 2006. The median follow-up time was 3.6
years (range, 0.2 to 6.0 years). Tumors were confirmed
histopathologically and staged according to the TNM
classification [35]. All patients who underwent breast-
conserving surgery were administered post-operative
radiotherapy. Adjuvant chemotherapy was performed
either by an anthracycline-based regimen (doxorubicin
or epirubicin) or by a 5FU-based regimen in TNBC
depending on the stage or risk of recurrence in accor-
dance with the National Comprehensive Cancer Net-
work (NCCN) guidelines [36]. This study was conducted
with the consent of the ethical committee of Osaka City
University, and informed consent was obtained from all
subjects. Overall survival time was set in days as the
period from the initial surgery.
Immunohistochemistry
Immunohistochemical study was performed as pre-
viously reported [37]. Briefly, the formalin embedded tis-
sue sections were deparaffinized, and were heated in
Target Retrieval Solution (Dako, Carpinteria, CA, USA).
Sections were then incubated in 10% normal goat or
rabbit serum to reduce non-sp e c i f i ca n t i b o d yb i n d i n g .
Tissue sections were then incubated with each primary
monoclonal antibody against ER (clone 1D5, dilution
1:80; Dako, Cambridge, UK), PR (clone PgR636, dilution
1:100; Dako), HER2 (Hercep Test, Dako), p53 (clone
DO-7, dilution 1:50; Dako), Ki67 (clone MIB-1, dilution
1:00; Dako) and E-cadherin (clone NCH-38, dilution
1:200; Dako). The slides were treated with streptavidin-
peroxidase reagent, and were incubated in PBS diamino-
benzidine and 1% hydrogen peroxide v/v, followed by
counterstaining with Mayer’s hematoxylin. Positive and
negative controls for each marker were used according
to the supplier’s data sheet (Dako). Immunohistochem-
ical scoring was performed in a blind fashion. The cut-
off for ER positivity and PR positivity was > 0% positive
tumor cells with nuclear staining. HER2 was graded
according to the accepted grading scheme as 0, 1+, 2+,
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reactivity or membranous reactivity in less than 10% of
cells; 1+, faint/barely perceptible membranous reactivity
in 10% of cells or higher or reactivity in only part of the
cell membrane; 2+, weak to moderate complete or baso-
lateral membranous reactivity in 10% of tumor cells or
higher; 3+, strong complete or basolateral membranous
reactivity in 10% of tumor cells or higher. HER-2 was
considered to be positive if immunostaining was 3+ or if
a 2+ result showed gene amplication by fluorescent in
situ hybridization (FISH). In FISH analyses, each copy of
the HER2 gene and its centromere 17 (CEP17) reference
were counted. The interpretation followed the criteria of
the ASCO/CAP guidelines for HER2 IHC interpretation
for breast cancer [38]: positive if the HER2/CEP17 ratio
was higher than 2.2. The cut-off for p53 was ≥ 1% posi-
tive tumor cells with nuclear staining. Ki67-labelling
index > 30% was determined to be positive. E-cadherin
antibody intensely stained the membrane and weakly
stained the cytoplasm of cancer cells. E-cadherin expres-
sion was semi-quantitatively analyzed according to the
percentage of cells showing membrane positivity: 0, 0 to
10%; 1+, 10 to 30%; 2+, 30 to 70%; 3+, > 70%. E-cad-
herin expression was considered positive when scores
were ≥ 2, and negative when scores were ≤ 1. Cytoplas-
mic staining only was not included in the assessment. E-
cadherin antibody intensely stained the membrane and
weakly stained the cytoplasm of cancer cells. A case
with cytoplasmic staining only was determined as E-cad-
herin negative, as shown with “score 0” (Figure 1).
Statistical analysis
Statistical analysis was performed using SPSS 13.0 statis-
t i c a ls o f t w a r e( S P S SI n c ,C h i c a g o ,I L ,U S A ) .W ee x a m -
ined the association between TNBC and other
clinicopathologic variables, and the significance of differ-
ent prognostic markers using chi-squared test, and chi-
squared test for trend as appropriate. The association
with survival was analyzed initially by Kaplan-Meier plot
and log-rank test and also with Cox regression analysis
to adjust for other prognostic indicators. A P-value of <
0.05 was considered significant. Cutoff values for differ-
ent biomarkers included in this study were chosen
before statistical analysis.
Results
The prognostic value of adjuvant chemotherapy in triple-
negative breast cancer
Cases that were negative for ER, PR and HER2 expres-
sion were considered to be cases of TNBC. Among the
total 1,036 breast cancer cases, there were 190 (18.3%)
cases of TNBC. Adjuvant chemotherapy was performed
p53 Ki67 E-cadherin
positive
negative
100% 70%  77% 
0% 0 % 0 % 
Figure 1 Immunohistochemical determination of E-cadherin, Ki67, and p53. E-cadherin was observed at cell-cell boundaries of breast
cancer cells. Ki67 and p53 were found in the nuclei of cancer cells. E-cadherin, Ki67 and p53 expressions were evaluated by percentage of
stained tumor cells. The upper paragraph showed positive-staining of E-cadherin (100%), Ki67 (70%) and p53 (77%), and the lower paragraph
showed as negative-staining (0%) as score 0.
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Page 3 of 12for 138 (72.6%) of the 190 TNBC cases; 60 cases had an
anthracyclin-based regimen and 78 a 5FU-based regi-
men (Table 1). The remaining 52 cases received surgery
alone. Among the 190 TNBC cases, those receiving sur-
gery plus adjuvant therapy (n = 138) had a more favor-
able prognosis (P = 0.0043) than those undergoing
surgery alone (n = 52) (Figure 2a). When restricting the
analysis to patients with Stage II cancers, the overall
survival of the surgery plus adjuvant chemotherapy
group was significantly better than that of the surgery
alone group (P = 0.0013) (Figure 2b). In contrast, in
patients with Stage I and III cancers, no significant dif-
ference of overall survival was found between the sur-
gery plus adjuvant chemotherapy group and the surgery
alone group (Additional file 1). There was no significant
difference in the prognosis of TNBC patients receiving
adjuvant therapy between the anthracyclin-based regi-
men and 5FU-based regimen (Table 2).
Significance of E-cadherin, Ki67, and p53 expression in
triple-negative breast cancer
Expression of E-cadherin, Ki67, and p53 was positive in
109 (57%), 65 (34%) and 118 (62%) of 190 cases of
TNBC, respectively (Table 3). The Ki67 expression level
was significantly high in Stage II and III TNBC tumors
(63%, P = 0.013). No significant association between E-
cadherin or p53 expression and clinicopathological para-
meters was identified in TNBC. The cases with E-cad-
herin-negative and Ki67-positive expression had a
significantly higher incidence of lymph node metastasis
(45%, P = 0.027).
TNBC with reduced E-cadherin expression showed a
significantly worse overall survival time (P = 0.0054, log-
rank), and cases with Ki67 expression showed signifi-
cantly worse overall survival time (P = 0.0181, log-rank)
(Figure 3a). Patients with E-cadherin-negative and Ki67-
positive expression showed a significantly worse overall
survival time (P = 0.001, log-rank). The prognosis of the
E-cadherin-negative cancer patients was significantly
poorer than that of the E-cadherin-positive cancer
patients in regard to overall survival at Stage II (P =
0.0058) (Figure 3b). The prognosis of the combination
of E-cadherin-negative and Ki67-positive expression
cancer patients was significantly poorer than that of the
combination of E-cadherin-positive and Ki67-negative
expression cancer patients in regard to overall survival
at Stage II (P = 0.0376) (Figure 3b) and Stage I (P =
0.0437) (Additional file 2). The combination of E-cad-
herin-negative and Ki67-positive expression was revealed
to be a more significant prognostic indicator than either
E-cadherin or Ki67 expression alone by multivariate
analyses (P = 0.004, OR = 2.784), while a univariate ana-
lysis revealed that the overall survival was significantly
correlated with the E-cadherin expression, Ki67 expres-
sion, stage, tumor size and lymph node metastasis
(Table 2).
In the 138 TNBC cases undergoing surgery plus adju-
vant chemotherapy, the prognosis of patients with E-
cadherin-negative plus Ki67-positive expression was sig-
nificantly worse that the prognosis of patients with
either of these risk factors alone (P = 0.001), while no
significant difference in prognosis was found in the 52
TNBC cases undergoing surgery alone (Figure 4a). No
significant difference in prognosis was found between
the E-cadherin-negative and Ki67-positive cases under-
going surgery plus adjuvant chemotherapy (n =5 1 )a n d
surgery alone cases. A multiv a r i a t el o g i s t i cr e g r e s s i o n
analysis showed that the combination of E-cadherin-
negative and Ki67-positive expression was significantly
correlated with the overall survival of patients under-
going surgery plus adjuvant chemotherapy (P = 0.001),
but not in those undergoing surgery alone, suggesting
that E-cadherin-negative and Ki67-positive expression is
an independent prognostic factor for TNBC with adju-
vant chemotherapy (Table 4). In the adjuvant che-
motherapy group, the overall survival of TNBC patients
having both E-cadherin-negative and Ki67-positive
expression was significantly worse than that of patients
with either risk factor alone at each of Stages II (Figure
4), I and III (Additional file 3). In contrast, no signifi-
cant difference in prognosis in relation to the Ki67
expression and/or E-cadherin expression was found in
52 cases without adjuvant chemotherapy at each of
Stages II (Figure 4), I and III (Additional file 3).
Discussion
Among the total 1,036 breast cancer cases, 190 (18.3%)
were cases of TNBC. NCCN guidelines and the St. Gal-
len consensus conference recommend adjuvant che-
motherapy for TNBC [26], although a specific regimen
for such adjuvant treatment has yet to be presented. In
Table 1 Regimen of chemotherapy in triple-negative
breast cancers
Adjuvant chemotherapy regimen Number of
patients
Anthracyclin-base 60
fluorouracil+epirubicin+cyclophosphamide (FEC) 34
epirubicin+cyclophosphamide (EC) 12
adriamycin+cyclophosphamide (AC) 11
cyclophosphamide+adriamycin+fluorouracil (CAF) 3
non-Anthracyclin-base 78
tegafur-uracil (UFT) 61
cyclophosphamide+methotorexate+fluorouracil
(CMF)
10
doxifluridine (5’DFUR) 4
fluorouracil (5FU) 3
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undergoing surgery plus adjuvant therapy had a more
favorable prognosis than those receiving surgery alone,
only among those with Stage II disease, suggesting that
adjuvant therapy is indeed useful for TNBC patients as
t h eN C C Nr e c o m m e n d s ,a n di sm o s tr e l e v a n ta tS t a g e
II. In the adjuvant therapy group, both univariate and
multivariate analysis showed no significant difference in
prognosis between the anthracyclin-based regimen and
5FU-based regimen, although patients with the former
regimen showed a trend-level improvement in prognosis
over those with the latter. Larger studies might be
necessary to clarify the prognoses of anthracyclin-based
regimen and 5FU-based regimen.
Since reliable parameters to predict the chemosensitiv-
ity of TNBC have not been clinically available, the prog-
nostic value of E-cadherin, Ki67 and p53 expression for
the outcome of adjuvant chemotherapy was evaluated.
In the adjuvant chemotherapy group, the prognosis of
E-cadherin-negative and Ki67-positive patients was
All cases (n=190)
surgery + adjuvant therapy (n=138)
surgery alone (n=52)
p=0.0043
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Figure 2 Overall survival of patients with triple-negative breast cancer according to receipt of adjuvant therapy. (A) Patients who
underwent surgery plus adjuvant therapy showed a better prognosis than those who underwent surgery alone (P = 0.0043). (B) Prognosis of
patients according to the clinical stage. Overall survival of patients by adjuvant chemotherapy was significantly better at Stage II (P = 0.0013).
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tive or Ki67-negative patients at all stages. Taking these
results together, a multivariate logistic regression analy-
sis showed that the E-cadherin-negative and Ki67-posi-
tive expression was significantly correlated with overall
survival of patients receiving adjuvant chemotherapy.
Ki67 is a candidate predictive marker for chemosensitiv-
ity in all types of breast cancer [16,26]; however, Ki67
alone is not an independent prognostic factor for TNBC
with adjuvant chemotherapy. These findings suggested
that the combination of E-cadherin and Ki67 expression
could be of predictive value for TNBC patients treated
by the adjuvant chemotherapeutic regimen, only at
Stage II. On the other hand, in the group undergoing
surgery alone, no significant difference of prognosis was
found between E-cadherin-negative and Ki67-positive
patients (n = 17) and either E-cadherin-positive or Ki67-
negative patients (n = 35). Since the combination of E-
cadherin and Ki67 status might be a useful prognostic
marker for adjuvant chemotherapy in TNBC patients,
the adjuvant chemotherapy might have led to a better
prognosis for the 35 cases with both E-cadherin-positive
and Ki67-negative expression. In contrast, no significant
difference in prognosis was found between the E-cad-
herin-negative and Ki67-positive cases undergoing sur-
gery plus adjuvant chemotherapy and surgery alone
cases, which might suggest that the development of new
adjuvant treatment approaches is necessary for the E-
cadherin-negative and Ki67-positive TNBC patients.
The Ki67 expression level was significantly high in
Stages II and III TNBC tumors (63%, P =0 . 0 1 3 ) .T h e s e
findings suggested that tumor cells at an advanced stage
might have higher proliferative activity than those at an
early stage.
The mechanisms responsible for the chemosensitivity
of TNBC with E-cadherin-negative and Ki67-positive
expression remain to be determined. Loss of E-cadherin
induces epithelial-to-mesenchymal transition (EMT).
EMT is a key step toward cancer metastasis. Ahmed et
al. reported the close relationship between EMT and
the cancer stem cell-like phenotype in response to che-
moresistance [39]. Also, other studies have shown that
Snail, Slug and Notch signaling, as EMT markers, were
correlated with chemoresistance. These findings sug-
gested that one of the possible mechanisms by which
chemosensitivity is reduced in patients with TNBC with
loss of E-cadherin expression may involve EMT signal-
ing [22,37]. In contrast, several studies have reported
that E-cadherin-dependent intercellular adhesion
enhances chemoresistance [40-42]. The function of E-
cadherin in the efficacy of chemotherapy is controver-
sial. Further studies of the correlation between E-cad-
herin and chemosensitivity in TNBC might be
necessary. Previous studies have demonstrated correla-
tions between Ki67 expression and malignancy as well
as patient outcomes [43,44]. Ki67 is one of the markers
for chemosensitivity in breast carcinomas, but little cor-
relation has been revealed between Ki67 expression and
Table 2 Univariate and multivariate analysis with respect to overall survival in 190 triple-negative breast cancers
Univarite analysis Multivariate analysis
Parameters Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Regimen
Anthracyclin-base vs 5FU-base
0.38 0.13 to 1.08 0.068 0.46 0.15 to 1.38 0.164
E-cadherin
Negative vs Positive 0.25 0.09 to 0.72 0.010 0.26 0.09 to 0.76 0.013
Ki67
Negative vs Positive 2.38 1.14 to 4.99 0.022 2.11 0.96 to 4.63 0.062
E-cadherin (-) and Ki67 (+)
Negative vs Positive 3.03 1.54 to 5.98 0.001 2.78 1.38 to 5.60 0.004
p53
Negative vs Positive 1.60 0.75 to 3.42 0.229 1.13 0.51 to 2.52 0.758
Stage
1 vs 2, 3, 4 2.54 1.04 to 6.22 0.041 0.30 0.05 to 2.00 0.214
Tumor size
≤ 2 cm vs > 2 cm 2.46 1.11 to 5.45 0.027 3.25 0.75 to 14.15 0.116
Lymph node status
N0 vs N1, N2, N3 3.40 1.68 to 6.91 0.001 3.46 1.38 to 8.66 0.008
Lymph-vascular invasion
Negative vs Positive 1.84 0.94 to 3.58 0.074 1.36 0.68 to 2.74 0.390
Nuclear grade
1, 2, vs 3 2.36 1.07 to 5.21 0.034 1.93 0.58 to 6.39 0.282
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Page 7 of 12chemosensitivity in the triple-negative phenotype. In this
study, we found that Ki67 expression had a prognostic
value for the outcome of adjuvant chemotherapy in
TNBC when it was combined with E-cadherin expres-
sion, but that Ki67 alone was not an independent prog-
nostic factor.
CR Kennedy et al. reported that patients with TNBC
who underwent adjuvant chemotherapy were less likely
to die compared with those who received neoadjuvant
chemotherapy or no chemotherapy. In contrast, our
study reported that the adjuvant therapy is beneficial for
Stage II TNBC patients. Moreover, we suggested that
the combination of E-cadherin and Ki67 status might be
a useful prognostic marker indicating the need for adju-
vant chemotherapy in Stage II TNBC patients. These
findings are novel in our study regarding the advantages
of adjuvant chemotherapy. TNBC patients have a
greater risk of distant metastasis [45,46]. The presence
of micrometastasis in the bone marrow at the time of
diagnosis of breast cancer is associated with a high risk
of relapse and a poor prognosis [47,48]. Patients with
bone marrow micrometastasis had tumors with a higher
stage as defined by tumor size and lymph-node status,
and hormone receptor-negative tumors [48-50]. These
findings suggested that the observed survival benefit of
adjuvant chemotherapy at Stage II may be a result of
the decreased opportunity for systemic tumor shedding
and growth of systemic micrometastases. Therefore, the
benefit of primary tumor removal followed by adjuvant
therapy may be clinically relevant for the TNBC at Stage
II.
No significant difference of overall survival was
found between the surgery alone group and the sur-
gery plus adjuvant chemotherapy group at Stages I and
III, while the surgery plus adjuvant therapy showed a
better prognosis than the surgery alone (Additional file
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Figure 3 Survival of patients with triple-negative breast cancer based on E-cadherin and Ki67 expression. (A) TNBC with reduced E-
cadherin expression showed a significantly worse overall survival time (P = 0.0054), and cases with Ki67 expression showed significantly worse
overall survival time (P = 0.0181). Patients with E-cadherin-negative and Ki67-positive expression showed a significantly worse overall survival
time (P = 0.001). (B) The prognosis of the E-cadherin-negative cancer patients was significantly poorer than that of the E-cadherin-positive
cancer patients in regard to overall survival (P = 0.0058) in Stage II. The prognosis of the combination of E-cadherin-negative and Ki67-positive
expression cancer patients was significantly poorer than that of the combination of E-cadherin-positive and Ki67-negative expression cancer
patients in regard to overall survival and in Stage II (P = 0.0376).
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Page 8 of 121). The recurrence rate of patients at Stage I was low
and the sample size of patients at Stage III was small
(n = 24) in this study, which might suggest one of the
reasons why findings may be limited to Stage II. A lar-
g e rn u m b e ro fT N B Cp a t i e n t sw i t hS t a g e sIa n dI I I
might be necessary to clarify whether patients with
Stages I and III also have these advantages by adjuvant
chemotherapy.
The p53 expression was positive in 118 (62%) of 190
cases of TNBC in the present study, which was similar
to previous reports of the p53 expression rate (42% to
56%) in TNBC [8,32,51]. p53 status was not a specific
prognostic factor in TNBC patients treated by adjuvant
chemotherapy. There have been many studies on the
predictive role of p53 for patients treated with anthra-
cyclines, but most of these studies were performed in a
neoadjuvant setting, and thus the value of p53 for pre-
dicting the efficacy of chemotherapy remains a matter
of controversy [27,28,30]. Chae et al. reported that p53
status was a specific prognostic factor in 135 TNBC
patients treated with an adjuvant anthracycline-based
regimen, although, as the authors pointed out, the
sample size was small [32]. Two of the main explana-
tions for the discrepancies among these studies are
that different methods were used to assess the p53 sta-
tus, and the groups were different in terms of the
patient characteristics and drug regimens. Because our
study was also heterogeneous in terms of the
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Figure 4 Significance of E-cadherin and Ki67 expression in patients with or without adjuvant therapy. (A) In 138 patients who
underwent adjuvant therapy, the Kaplan-Meier survival curve showed that a statistically significant difference in the survival was observed in
relation to the Ki67 expression and/or E-cadherin expression (P = 0.001). In contrast, no significant difference of prognosis in relation to the Ki67
expression and/or E-cadherin expression was found in 52 cases without adjuvant chemotherapy (P = 0.7768). (B) The prognosis of E-cadherin-
negative and Ki67-positive patients was significantly poorer than that of the E-cadherin-positive or Ki67-negative patients at Stage II (P = 0.0316).
In contrast, no significant difference of prognosis in relation to the Ki67 expression and/or E-cadherin expression was found in 22 cases without
adjuvant chemotherapy at Stage II (P = 0.9427).
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Page 9 of 12chemotherapy regimen, a larger sample size with a sin-
gle regimen might be necessary to evaluate the clinical
significance of p53 for TNBC patients with adjuvant
chemotherapy.
Conclusions
In conclusion, adjuvant therapy is beneficial for TNBC
patients, only at Stage II. The combination of E-cad-
herin and Ki67 status might be a useful prognostic mar-
ker indicating the need for adjuvant chemotherapy in
Stage II TNBC patients.
Additional material
Additional file 1: File showing overall survival of patients at Stages
I and III according to receipt of adjuvant therapy. When restricting
the analysis to patients with Stages I (A) and III (B) cancers, the overall
survival of the surgery plus adjuvant chemotherapy group was not
significantly better than that of the surgery alone group.
Additional file 2: File showing survival of patients at Stages I and III
based on E-cadherin expression and Ki67 expression. (A) The
prognosis of the combination of E-cadherin-negative and Ki67-positive
expression cancer patients was significantly poorer than that of the
combination of E-cadherin-positive and Ki67-negative expression cancer
patients at Stage I (P = 0.0437). (B) In contrast, no significant difference
was found at Stage III.
Additional file 3: File showing significance of E-cadherin and Ki67
expression in patients with or without adjuvant therapy. In surgery
plus adjuvant chemotherapy group, the overall survival of TNBC patients
having both E-cadherin-negative and Ki67-positive expression was
significantly worse than that of patients with E-cadherin-positive and
Ki67-negative at Stages I and III. In contrast, no significant difference was
found in surgery alone group.
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Table 4 Univariate and multivariate analysis with respect to overall survival of 138 TNBC patients with surgery plus
adjuvant chemotherapy or 52 TNBC patients with surgery alone
Patients with chemotherapy (n = 138) Patients without chemotherapy (n = 52)
Univarite analysis Multivariate analysis Univarite analysis Multivariate
analysis
Parameters Odds
ratio
95% CI P-
value
Odds
ratio
95% CI P-
value
Odds
ratio
95% CI p
value
Odds
ratio
95% CI P-
value
Ki67 (+) and E-
cadherin (-)
Negative vs Positive
6.69 2.41 to
18.62
<0.001 5.84 2.03 to
16.76
0.001 1.16 0.41 to
3.28
0.777 0.76 0.20 to
2.94
0.688
E-cadherin
Negative vs Positive
0.02 0.00 to
1.16
0.060 0.00 0.00 to
1.98
0.943 1.00 0.32 to
3.16
0.998 1.53 0.44 to
5.36
0.503
Ki67
Negative vs Positive
3.09 1.11 to
8.66
0.032 2.60 0.87 to
7.76
0.086 1.81 0.62 to
5.31
0.282 1.89 0.42 to
8.50
0.407
p53
Negative vs Positive
1.61 0.58 to
4.45
0.361 0.98 0.34 to
2.85
0.975 1.61 0.58 to
4.45
0.361 1.86 0.54 to
6.45
0.327
Stage
1v s2 ,3 ,4
2.56 0.73 to
8.99
0.144 0.15 0.01 to
2.45
0.185 4.22 1.17 to
15.28
0.028 1.28 0.06 to
23.36
0.872
Tumor size
≤ 2c mv s> 2c m
2.63 0.86 to
8.01
0.089 4.23 0.54 to
33.34
0.171 23.26 1.02 to
10.38
0.046 1.65 0.16 to
16.58
0.670
Lymph node status
N0 vs N1, N2, N3
4.69 1.67 to
13.16
0.003 5.71 1.25 to
26.20
0.025 5.63 1.68 to
18.93
0.005 5.10 1.08 to
23.94
0.039
Lymphvascular
invasion
Negative vs Positive
2.09 0.86 to
5.07
0.103 1.34 0.52 to
3.44
0.548 1.32 0.48 to
3.63
0.597 0.94 0.29 to
3.09
0.922
Nuclear grade
1, 2, vs 3
2.87 0.94 to
8.72
0.063 1.64 0.51 to
5.28
0.405 1.22 0.39 to
3.86
0.732 0.99 0.25 to
3.96
0.988
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